Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ
Published January 15, 2025 · Recall initiated: December 30, 2024
Summary
FDA records drug Class II recall D-0190-2025, published January 15, 2025 and initiated December 30, 2024. Recalling firm: Rising Pharma Holding, Inc.; Status: Ongoing; Reported quantity: 244,460 bottles; Lot: Lot # a) DT6023053A, DT6023061A, DT6023068A, DT6023074A, exp. date Jan-25; DT6023078A, DT6023076A, exp. date Feb-25; DTC24043A, DTC24044A, exp. date Dec-25 b) DT6023002A, DT6023016A, DT6023036A, exp. date Dec-24; DT6023048A, exp. date Jan-25. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Rising Pharma Holding, Inc.
- Distributor
- Nationwide
- Lot
- Lot # a) DT6023053A, DT6023061A, DT6023068A, DT6023074A, exp. date Jan-25; DT6023078A, DT6023076A, exp. date Feb-25; DTC24043A, DTC24044A, exp. date Dec-25 b) DT6023002A, DT6023016A, DT6023036A, exp. date Dec-24; DT6023048A, exp. date Jan-25
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDARising, Cyproheptadine Hydrochloride Syrup, 2mg/5 mL, 473 mL (ONE PINT), Rx only, Manufactured for: RisingJuly 29, 2026
- FDAProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: RisingMarch 11, 2026
- FDACarbidopa, Levodopa, Entacapone Tablets, 25 mg/100 mg/200 mg, 100-count bottle, Rx Only, Manufactured for:October 22, 2025
- FDADuloxetine Delayed-Release Capsules, USP, 30 mg, 1,000-count bottle, Rx only, Distributed by: Rising Health,March 26, 2025
- FDADuloxetine Delayed-Release Capsules USP 20 mg, 60 count bottles, Rx only, Distributed by: Rising PharmJanuary 15, 2025
- FDAKit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection, 10 mL Multi-Dose Reaction Vial, 5 vialJanuary 15, 2025
Questions about this recall
Was Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ recalled?
Yes. FDA published recall D-0190-2025 on January 15, 2025. Reported hazard: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
What should I do if I have this product?
Voluntary: Firm initiated · Letter